

LUN100_Exclusion criteria

Exclusion

- Mixed SCLC and NSCLC histology.
- Active second malignancy. Note: Patients with a history of malignancy who have been completely treated, with no evidence of cancer for 3 years prior to enrollment, or patients with surgically cured tumors with low risk of recurrence (eg, nonmelanoma skin cancer, histologically-confirmed complete excision of carcinoma in situ, or similar) are allowed to enroll.
- Patients may not have received systemic anticancer treatment within the previous 6 months or radiation therapy within 2 weeks prior to enrollment.
- Patients must have recovered (i.e., > Grade 2 is considered not recovered) from AEs at the time of study entry.
- Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
- A 1-week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-central nervous system (CNS) disease. Note: Patients with any grade alopecia are an exception to this criterion and will qualify for the study.
- Note: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
- Have previously received treatment with any of the following:
Topoisomerase 1 inhibitors. Any agent including an ADC containing a chemotherapeutic agent targeting topoisomerase 1. Trop-2-targeted therapy.